BriaCell Therapeutics (BCTX) News Today $0.68 +0.08 (+12.50%) (As of 10:25 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer StudyNovember 21 at 7:50 AM | globenewswire.comBriaCell reports preclinical data of personalized off-the-shelf immunotherapiesNovember 9, 2024 | markets.businessinsider.comBriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC ConferenceNovember 8, 2024 | globenewswire.comBriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13November 4, 2024 | globenewswire.comBriaCell announces survival data from Phase 2 metastatic breast cancer studyOctober 22, 2024 | markets.businessinsider.comBriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival DataOctober 22, 2024 | globenewswire.comBriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal StudyOctober 15, 2024 | globenewswire.comBriaCell Therapeutics Announces Closing of $5 Million OfferingOctober 2, 2024 | globenewswire.comBriaCell Therapeutics Announces $5 Million OfferingOctober 1, 2024 | globenewswire.comBriaCell dips despite promising mid-stage data for breast cancer therapyOctober 1, 2024 | seekingalpha.comBriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” TumorOctober 1, 2024 | globenewswire.comBriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer PatientsSeptember 18, 2024 | globenewswire.comBriaCell Therapeutics Announces Closing of $8.5 Million OfferingSeptember 12, 2024 | globenewswire.comBriaCell Therapeutics Shares Retreat From Earlier Surge After Stock OfferingSeptember 11, 2024 | marketwatch.comBriaCell Therapeutics Announces $8.5 Million OfferingSeptember 11, 2024 | globenewswire.comWhy Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On WednesdaySeptember 11, 2024 | benzinga.comBriaCell Reports Positive Overall Survival (OS) in Metastatic Breast CancerSeptember 11, 2024 | globenewswire.comBriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate CancerSeptember 10, 2024 | globenewswire.comBriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingSeptember 9, 2024 | globenewswire.comBriacell Therapeutics Corp (BCT)August 15, 2024 | investing.comBriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast CancerJuly 18, 2024 | globenewswire.comBriaCell Presents Clinical Efficacy Data at ASCO 2024June 3, 2024 | globenewswire.comBriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024May 24, 2024 | globenewswire.comBriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingMay 17, 2024 | globenewswire.comBriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct OfferingMay 15, 2024 | globenewswire.comBriaCell Announces Oral and Poster Presentations at ASCO 2024April 24, 2024 | globenewswire.comBriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate CancerApril 10, 2024 | globenewswire.comBriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACRApril 9, 2024 | finance.yahoo.comBriaCell Therapeutics Corp. (BCTX)March 20, 2024 | sg.finance.yahoo.comBriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer ImmunotherapiesMarch 7, 2024 | globenewswire.comBriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR ConferenceMarch 6, 2024 | globenewswire.comBriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesFebruary 27, 2024 | finance.yahoo.comBriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesFebruary 27, 2024 | globenewswire.comBriaCell Therapeutics Corp. (BCTX) stock forecast and price targetFebruary 14, 2024 | finance.yahoo.comBriaCell Therapeutics (NASDAQ:BCTX) Trading 5.3% Higher BriaCell Therapeutics (NASDAQ:BCTX) Trading Up 5.3%February 7, 2024 | marketbeat.comBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingJanuary 30, 2024 | finance.yahoo.comBriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer PatientsDecember 28, 2023 | finance.yahoo.comBriaCell Therapeutics Stock (NASDAQ:BCTX) Dividends: History, Yield and DatesDecember 27, 2023 | benzinga.comBriaCell Therapeutics' Cancer Drug Shows Preliminary Survival, Clinical Benefit In Pretreated PatientsDecember 20, 2023 | msn.comBriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient SubsetDecember 20, 2023 | finance.yahoo.comBriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCSDecember 6, 2023 | finance.yahoo.comBCTX: November 2023 SITC PosterNovember 8, 2023 | finance.yahoo.comBriaCell Therapeutics Corp Ordinary Shares - New BCTXNovember 4, 2023 | morningstar.comBCTX: Year in ReviewNovember 1, 2023 | finance.yahoo.comBriaCell Therapeutics Corp Ordinary Shares - NewOctober 24, 2023 | morningstar.comBriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo ClinicOctober 11, 2023 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing ShareholdersAugust 31, 2023 | finance.yahoo.comBriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast CancerAugust 31, 2023 | finance.yahoo.comBriaCell receives court approval to launch spinoff aimed at accelerating cancer drug developmentAugust 28, 2023 | bizjournals.comBCTX: Pivotal Study Protocol ClearedJuly 10, 2023 | finance.yahoo.com Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. BCTX Media Mentions By Week BCTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCTX News Sentiment▼0.000.46▲Average Medical News Sentiment BCTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCTX Articles This Week▼00▲BCTX Articles Average Week Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MIST News MNOV News ADAG News KPTI News ELYM News ANL News IMUX News NVCT News ASMB News EPRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCTX Stock Alerts